Can intra‑articular methylprednisolone be administered?

Yes, methylprednisolone can be administered intra-articularly

Intra-articular methylprednisolone is an established and appropriate treatment option for joint inflammation, particularly in acute gout (1-2 large joints) and knee osteoarthritis with pain flares. The evidence from multiple guidelines and FDA labeling confirms this route of administration is both safe and effective when used appropriately.

Approved Indications and Evidence

Acute Gout

The 2012 American College of Rheumatology guidelines specifically recommend intra-articular corticosteroids for acute gout involving 1-2 large joints (Evidence B) 1. The dosing should be based on joint size, and this can be combined with oral corticosteroids, NSAIDs, or colchicine 1. While the guidelines mention oral methylprednisolone dose packs as an option, they explicitly endorse intra-articular corticosteroid therapy as a first-line choice for oligoarticular gout.

Knee Osteoarthritis

Multiple EULAR and international guidelines support intra-articular corticosteroid use for knee OA:

• For acute flares with effusion: The 2003 EULAR recommendations state that "intra-articular injection of long acting corticosteroid is indicated for flare of knee pain, especially if accompanied by effusion" (Evidence 1B) 2

• For persistent pain: The 2021 OARSI/ESCEO guidelines recommend intra-articular corticosteroids when first-line treatments fail, noting effectiveness for 2-4 weeks 3

• Specific methylprednisolone evidence: A 2018 meta-analysis demonstrated that intra-articular methylprednisolone significantly improved WOMAC pain scores at 4,12, and 24 weeks, with no severe adverse effects 4

However, an important caveat: A randomized crossover study found no clinical predictors of response to methylprednisolone versus saline, suggesting the injection shouldn't be reserved only for patients with effusion 2.

FDA-Approved Dosing and Technique

The FDA labeling for methylprednisolone acetate (Depo-Medrol) explicitly includes intra-articular administration 5:

• Dose range: 4-80 mg depending on joint size
• Large joints (knee, ankle, shoulder): 20-80 mg
• Medium joints: 10-40 mg
• Small joints: 4-10 mg

Critical technique points 5:

• Aspirate joint fluid first if present
• Leave needle in place and switch syringes
• Inject into joint space, NOT into cartilage or tendon substance
• Use sterile technique throughout

Safety Considerations and Contraindications

Absolute Contraindications 5

• Systemic fungal infections (except for localized joint conditions)
• Hypersensitivity to methylprednisolone
• Never use intrathecally (associated with severe adverse events)

Important Precautions

Timing relative to surgery: The 2021 VA/DoD guidelines recommend avoiding corticosteroid injection for 3 months before joint replacement surgery due to infection risk 6. The 2021 EULAR recommendations state injections "may be performed at least 3 months prior to joint replacement" 7.

Frequency limitations: Limit to one injection every 6 weeks, maximum 3-4 injections per year in the same joint to minimize cartilage damage risk 8

Systemic absorption: Peak serum methylprednisolone levels occur 2-12 hours post-injection, with cortisol suppression lasting up to 1 week 9. In one study, 25% of patients developed transient secondary adrenal insufficiency between weeks 2-4 after an 80 mg knee injection 10

Diabetic patients: Must be warned about transient hyperglycemia, particularly days 1-3 post-injection, and advised to monitor glucose levels 7

Anticoagulation: While not an absolute contraindication, ensure INR is within therapeutic range for warfarin patients; exercise greater caution with novel oral anticoagulants due to limited safety data 11

Clinical Decision Algorithm

1. Confirm indication: Acute gout (1-2 large joints) OR knee OA with persistent pain/flare
2. Rule out infection: Absolutely mandatory before injection
3. Check contraindications: Systemic fungal infection, upcoming surgery (<3 months)
4. Assess joint: Aspirate if effusion present (both diagnostic and therapeutic)
5. Dose selection: 40-80 mg for large joints (knee), 20-40 mg for medium joints
6. Technique: Sterile preparation, intra-articular placement confirmed
7. Post-injection: Avoid overuse for 24 hours, but don't immobilize 7
8. Follow-up: Monitor diabetics for hyperglycemia; reassess at 2-4 weeks

Common Pitfalls to Avoid

• Don't inject into tendons or ligaments - causes tissue necrosis with methylprednisolone 5
• Don't use for polyarticular disease - systemic therapy more appropriate 1
• Don't repeat too frequently - respect 6-week intervals 8
• Don't assume effusion predicts response - evidence shows benefit even without effusion 2
• Don't forget about systemic effects - HPA axis suppression occurs even with local injection 9, 10

The evidence strongly supports intra-articular methylprednisolone as an effective, guideline-endorsed treatment when used judiciously with proper technique and patient selection.